These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
679 related articles for article (PubMed ID: 8103403)
1. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Donis-Keller H; Dou S; Chi D; Carlson KM; Toshima K; Lairmore TC; Howe JR; Moley JF; Goodfellow P; Wells SA Hum Mol Genet; 1993 Jul; 2(7):851-6. PubMed ID: 8103403 [TBL] [Abstract][Full Text] [Related]
2. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas. Komminoth P Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671 [TBL] [Abstract][Full Text] [Related]
3. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Hofstra RM; Landsvater RM; Ceccherini I; Stulp RP; Stelwagen T; Luo Y; Pasini B; Höppener JW; van Amstel HK; Romeo G Nature; 1994 Jan; 367(6461):375-6. PubMed ID: 7906866 [TBL] [Abstract][Full Text] [Related]
4. [Early diagnosis of multiple endocrine neoplasia type 2 (MEN 2) by detection of mutated RET proto-oncogene carriers]. Sansó G; Domené HM; Iorcansky S; Barontini M Medicina (B Aires); 1998; 58(2):179-84. PubMed ID: 9706252 [TBL] [Abstract][Full Text] [Related]
5. Mutation analysis of the RET proto-oncogene in Dutch families with MEN 2A, MEN 2B and FMTC: two novel mutations and one de novo mutation for MEN 2A. Landsvater RM; Jansen RP; Hofstra RM; Buys CH; Lips CJ; Ploos van Amstel HK Hum Genet; 1996 Jan; 97(1):11-4. PubMed ID: 8557249 [TBL] [Abstract][Full Text] [Related]
6. A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. Eng C; Smith DP; Mulligan LM; Healey CS; Zvelebil MJ; Stonehouse TJ; Ponder MA; Jackson CE; Waterfield MD; Ponder BA Oncogene; 1995 Feb; 10(3):509-13. PubMed ID: 7845675 [TBL] [Abstract][Full Text] [Related]
7. Germline RET mutations in MEN 2A and FMTC and their detection by simple DNA diagnostic tests. Xue F; Yu H; Maurer LH; Memoli VA; Nutile-McMenemy N; Schuster MK; Bowden DW; Mao J; Noll WW Hum Mol Genet; 1994 Apr; 3(4):635-8. PubMed ID: 7915165 [TBL] [Abstract][Full Text] [Related]
8. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Mulligan LM; Eng C; Healey CS; Clayton D; Kwok JB; Gardner E; Ponder MA; Frilling A; Jackson CE; Lehnert H Nat Genet; 1994 Jan; 6(1):70-4. PubMed ID: 7907913 [TBL] [Abstract][Full Text] [Related]
9. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Mulligan LM; Kwok JB; Healey CS; Elsdon MJ; Eng C; Gardner E; Love DR; Mole SE; Moore JK; Papi L Nature; 1993 Jun; 363(6428):458-60. PubMed ID: 8099202 [TBL] [Abstract][Full Text] [Related]
10. Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas. Komminoth P; Kunz EK; Matias-Guiu X; Hiort O; Christiansen G; Colomer A; Roth J; Heitz PU Cancer; 1995 Aug; 76(3):479-89. PubMed ID: 8625130 [TBL] [Abstract][Full Text] [Related]
11. Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A (Sipple's syndrome). Oishi S; Sato T; Takiguchi-Shirahama S; Nakamura Y Endocr J; 1995 Aug; 42(4):527-36. PubMed ID: 8556060 [TBL] [Abstract][Full Text] [Related]
12. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Eng C; Smith DP; Mulligan LM; Nagai MA; Healey CS; Ponder MA; Gardner E; Scheumann GF; Jackson CE; Tunnacliffe A Hum Mol Genet; 1994 Feb; 3(2):237-41. PubMed ID: 7911697 [TBL] [Abstract][Full Text] [Related]
13. A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. Berndt I; Reuter M; Saller B; Frank-Raue K; Groth P; Grussendorf M; Raue F; Ritter MM; Höppner W J Clin Endocrinol Metab; 1998 Mar; 83(3):770-4. PubMed ID: 9506724 [TBL] [Abstract][Full Text] [Related]
14. Molecular analysis of the RET proto-oncogene in patients with sporadic medullary thyroid carcinoma: a novel point mutation in the extracellular cysteine-rich domain. Bugalho MJ; Frade JP; Santos JR; Limbert E; Sobrinho L Eur J Endocrinol; 1997 Apr; 136(4):423-6. PubMed ID: 9150704 [TBL] [Abstract][Full Text] [Related]
15. The RET proto-oncogene and cancer. Donis-Keller H J Intern Med; 1995 Oct; 238(4):319-25. PubMed ID: 7595167 [TBL] [Abstract][Full Text] [Related]
16. Novel point mutation in exon 10 of the RET proto-oncogene in a family with medullary thyroid carcinoma. Oriola J; Páramo C; Halperin I; García-Mayor RV; Rivera-Fillat F Am J Med Genet; 1998 Jul; 78(3):271-3. PubMed ID: 9677065 [TBL] [Abstract][Full Text] [Related]
17. "Cold" single-strand conformational variants for mutation analysis of the RET protooncogene. Musholt PB; Musholt TJ; Goodfellow PJ; Zehnbauer BA; Wells SA; Moley JF Surgery; 1997 Aug; 122(2):363-70; discussion 370-1. PubMed ID: 9288142 [TBL] [Abstract][Full Text] [Related]
18. RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma. Marsh DJ; Mulligan LM; Eng C Horm Res; 1997; 47(4-6):168-78. PubMed ID: 9167949 [TBL] [Abstract][Full Text] [Related]
19. High prevalence of the C634Y mutation in the RET proto-oncogene in MEN 2A families in Spain. Sánchez B; Robledo M; Biarnes J; Sáez ME; Volpini V; Benítez J; Navarro E; Ruiz A; Antiñolo G; Borrego S J Med Genet; 1999 Jan; 36(1):68-70. PubMed ID: 9950371 [TBL] [Abstract][Full Text] [Related]
20. Somatic and MEN 2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTC:s. Zedenius J; Wallin G; Hamberger B; Nordenskjöld M; Weber G; Larsson C Hum Mol Genet; 1994 Aug; 3(8):1259-62. PubMed ID: 7987299 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]